Results 41 to 50 of about 117 (67)

The SChISM study: Circulating cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

open access: yes
BackgroundCirculating cell-free DNA (cfDNA) offers a promising noninvasive way to predict resistance to immune-checkpoint inhibitors (ICI), for which robust biomarkers are still lacking.MethodsThe SChISM (Size CfDNA Immunotherapy Signature Monitoring ...
Boutonnet, Audrey   +11 more
core   +4 more sources

Integrating tumor kinetics and circulating cell-free DNA markers through mechanistic modeling for early prediction of immunotherapy response

open access: yes
International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression(EP), defined as progression at the first imaging evaluation.
Fina, Frederic   +7 more
core   +1 more source

Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors

open access: yes
International audienceIntroduction: Despite a significant proportion (20 to 40%)[1] of advanced cancer patients having long-term response to treatment with immune checkpoint inhibitors (ICI), many of them do not respond at all and experience early ...
Boutonnet, Audrey   +8 more
core   +2 more sources

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

open access: yes
International audienceAbstract Locally advanced esophageal carcinoma remains of poor prognosis correlated with tumor stage. Albeit liquid biopsy approach offers promising results to monitor high‐risk patients in various solid tumors, the lack of specific
Le Sourd, Samuel   +21 more
core   +1 more source

Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy

open access: yes
BackgroundPlasma cell-free DNA (cfDNA) shows promise as predictive cancer biomarker, but mechanisms governing cfDNA production/fragmentation/elimination dynamics, and their relationships with tumor burden and disease progression, remain poorly understood.
Boutonnet, Audrey   +9 more
core   +3 more sources

Cell-Free DNA Fragmentome Dynamics as a Biomarker for Immune-Checkpoint Inhibition in Advanced Carcinoma

open access: yes
International audienceEarly prediction of resistance to immunotherapy is a major challenge in oncology. The ongoing SChISM (Size Cell-fre DNA (cfDNA) Immunotherapies Signature Monitoring) clinical study proposes an innovative approach based on patented ...
Boutonnet, Audrey   +11 more
core   +1 more source

Holistic Integration of Deep Learning Models for Mass Spectrometry-Based Peptide Identification

open access: yes
Tandem mass spectrometry (MS/MS) coupled with liquid chromatography and/or ion mobility separation is an essential experimental technique for high-throughput discovery of the proteome, or the collection of proteins in a biological system.
Yang, Kevin
core   +1 more source

Combining cell-free DNA fragmentomes and total tumour volume improves prognostication and tumour response evaluation in patients with colorectal cancer liver metastases

open access: yes
Background: Treatment decisions in patients with unresectable colorectal liver metastases (CRLM) are largely guided by radiological response to induction systemic therapy.
Stoker, Jaap   +34 more
core  

Mechanistic Modeling of Joint Circulating Cell-free DNA Concentration—Tumor Size Kinetics under Immune-Checkpoint Inhibitors in Advanced Cancer

open access: yes
International audienceObjectivesIn cancer patients, the plasmatic concentration of global cfDNA — shed by both tumor and wild-type (especially immune) cells — rises and fluctuates with tumor size, number of metastases, and treatment[1].
Boutonnet, Audrey   +12 more
core   +2 more sources

Home - About - Disclaimer - Privacy